Arkolith/Insider Trading/MRTX/Form 4

Christensen Jamie

EVP & Chief Scientific OfficerMirati Therapeutics, Inc. (MRTX) · full profile →Form 4 · filed Jan 23, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
17
3 non-derivative · 14 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 23, 2024Disposed to issuer(D)17K——0
Jan 23, 2024Disposed to issuer(D)56K——99K
Jan 23, 2024Disposed to issuer(D)81K——17K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 23, 2024Disposed to issuer(D)9K——0
Jan 23, 2024Disposed to issuer(D)13K——0
Jan 23, 2024Disposed to issuer(D)14K——0
Jan 23, 2024Disposed to issuer(D)41K——0
Jan 23, 2024Disposed to issuer(D)5K——0
Jan 23, 2024Disposed to issuer(D)75K——0
Jan 23, 2024Disposed to issuer(D)1K——0
Jan 23, 2024Disposed to issuer(D)29K——0
Jan 23, 2024Disposed to issuer(D)2K——0
Jan 23, 2024Disposed to issuer(D)43K——0
Jan 23, 2024Disposed to issuer(D)1K——0
Jan 23, 2024Disposed to issuer(D)59K——0
Jan 23, 2024Disposed to issuer(D)1K——0
Jan 23, 2024Disposed to issuer(D)21K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001140361-24-003529) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML